Efficient Chimeric Antigen Receptor T-Cell Generation Starting with Leukoreduction System Chambers of Thrombocyte Apheresis Sets
© 2023 The Author(s). Published by S. Karger AG, Basel..
Introduction: Primary human blood cells represent an essential model system to study physiology and disease. However, human blood is a limited resource. During healthy donor plateletpheresis, the leukoreduction system chamber (LRSC) reduces the leukocyte amount within the subsequent platelet concentrate through saturated, fluidized, particle bed filtration technology. Normally, the LRSC is discarded after apheresis is completed. Compared to peripheral blood, LRSC yields 10-fold mononuclear cell concentration.
Methods: To explore if those retained leukocytes are attractive for research purposes, we isolated CD3+ T cells from the usually discarded LRSCs via density gradient centrifugation in order to manufacture CD19-targeted chimeric antigen receptor (CAR) T cells.
Results: Immunophenotypic characterization revealed viable and normal CD4+ and CD8+ T-cell populations within LRSC, with low CD19+ B cell counts. Magnetic-activated cell sorting (MACS) purified CD3+ T cells were transduced with CD19 CAR-encoding lentiviral self-inactivating vectors using concentrated viral supernatants. Robust CD19 CAR cell surface expression on transduced T cells was confirmed by flow cytometry. CD19 CAR T cells were further enriched through anti-CAR MACS, yielding 80% CAR+ T-cell populations. In vitro CAR T cell expansion to clinically relevant numbers was achieved. To prove functionality, CAR T cells were co-incubated with the human CD19+ B cell precursor leukemia cell line Nalm6. Compared to unmodified T cells, CD19 CAR T cells effectively eradicated Nalm6 cells.
Conclusion: Taken together, we can show that lymphocytes isolated from LRSCs of plateletpheresis sets can be efficiently used for the generation of functional CAR T cells for experimental purposes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:51 |
|---|---|
| Enthalten in: |
Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie - 51(2024), 2 vom: 01. Apr., Seite 111-118 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xhaxho, Stefani [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cell therapy |
|---|
| Anmerkungen: |
Date Revised 09.04.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1159/000532130 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370741102 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370741102 | ||
| 003 | DE-627 | ||
| 005 | 20240409232850.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240408s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000532130 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1370.xml |
| 035 | |a (DE-627)NLM370741102 | ||
| 035 | |a (NLM)38584695 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Xhaxho, Stefani |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficient Chimeric Antigen Receptor T-Cell Generation Starting with Leukoreduction System Chambers of Thrombocyte Apheresis Sets |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 09.04.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Author(s). Published by S. Karger AG, Basel. | ||
| 520 | |a Introduction: Primary human blood cells represent an essential model system to study physiology and disease. However, human blood is a limited resource. During healthy donor plateletpheresis, the leukoreduction system chamber (LRSC) reduces the leukocyte amount within the subsequent platelet concentrate through saturated, fluidized, particle bed filtration technology. Normally, the LRSC is discarded after apheresis is completed. Compared to peripheral blood, LRSC yields 10-fold mononuclear cell concentration | ||
| 520 | |a Methods: To explore if those retained leukocytes are attractive for research purposes, we isolated CD3+ T cells from the usually discarded LRSCs via density gradient centrifugation in order to manufacture CD19-targeted chimeric antigen receptor (CAR) T cells | ||
| 520 | |a Results: Immunophenotypic characterization revealed viable and normal CD4+ and CD8+ T-cell populations within LRSC, with low CD19+ B cell counts. Magnetic-activated cell sorting (MACS) purified CD3+ T cells were transduced with CD19 CAR-encoding lentiviral self-inactivating vectors using concentrated viral supernatants. Robust CD19 CAR cell surface expression on transduced T cells was confirmed by flow cytometry. CD19 CAR T cells were further enriched through anti-CAR MACS, yielding 80% CAR+ T-cell populations. In vitro CAR T cell expansion to clinically relevant numbers was achieved. To prove functionality, CAR T cells were co-incubated with the human CD19+ B cell precursor leukemia cell line Nalm6. Compared to unmodified T cells, CD19 CAR T cells effectively eradicated Nalm6 cells | ||
| 520 | |a Conclusion: Taken together, we can show that lymphocytes isolated from LRSCs of plateletpheresis sets can be efficiently used for the generation of functional CAR T cells for experimental purposes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cell therapy | |
| 650 | 4 | |a Chimeric antigen receptor T cell | |
| 650 | 4 | |a Leukoreduction system chamber | |
| 650 | 4 | |a T cell | |
| 700 | 1 | |a Chen-Wichmann, Linping |e verfasserin |4 aut | |
| 700 | 1 | |a Kreissig, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Windisch, Roland |e verfasserin |4 aut | |
| 700 | 1 | |a Gottschlich, Adrian |e verfasserin |4 aut | |
| 700 | 1 | |a Nandi, Sayantan |e verfasserin |4 aut | |
| 700 | 1 | |a Schabernack, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Kohler, Irmgard |e verfasserin |4 aut | |
| 700 | 1 | |a Kellner, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Kobold, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Humpe, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Wichmann, Christian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie |d 2006 |g 51(2024), 2 vom: 01. Apr., Seite 111-118 |w (DE-627)NLM163330360 |x 1660-3796 |7 nnns |
| 773 | 1 | 8 | |g volume:51 |g year:2024 |g number:2 |g day:01 |g month:04 |g pages:111-118 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1159/000532130 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 51 |j 2024 |e 2 |b 01 |c 04 |h 111-118 | ||